{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-22-013082","form_type":"8-K","ticker":"DMAC","cik":"0001401040","company_name":"DiaMedica Therapeutics Inc.","filed_at":"2022-05-19T23:59:59+00:00","discovered_at":"2026-05-14T18:04:00.483267+00:00","generated_at":"2026-06-25T09:08:28.624468+00:00","sec_items":["5.02","5.07","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"DiaMedica shareholders approve 2M share increase in 2019 omnibus incentive plan and new director compensation cap","bullets":["Shareholders approved amendment to 2019 Omnibus Incentive Plan, increasing authorized shares by 2,000,000.","The amended plan imposes a dollar limit on non-employee director compensation per calendar year.","All six director nominees were elected; Richard Pilnik received 3.4M for, 1.3M withheld.","Baker Tilly US, LLP appointed as independent registered public accounting firm for 2022.","The plan became effective May 18, 2022 and expires on May 21, 2029."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-22-013082","json":"https://secwatch.observer/filing/0001437749-22-013082.json","markdown":"https://secwatch.observer/filing/0001437749-22-013082.md","text":"https://secwatch.observer/filing/0001437749-22-013082.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1401040/000143774922013082/0001437749-22-013082-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1401040/000143774922013082/dmtp20220518_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T09:08:28.624468+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}